The patent expiry of the diabetes/obesity drug semaglutide is set to flood India's market with over 40 generic versions, potentially expanding access but raising significant safety, regulatory, and quality control challenges. This case study highlights the critical balance between drug affordability and ensuring robust pharmacovigilance for complex biologic medicines.
Exam Lens
Quick Exam Facts From News
1-Minute Revision
- ›Drug in Focus: Semaglutide
- ›Expected Generic Brands: 40+
- ›Target this Data: Over 40 generic brands expected post semaglutide patent expiry.
- ›Target this Nodal Body: Central Drugs Standard Control Organization (CDSCO) for drug regulation.
- ›Target this Concept: 'Complex peptide' vs. simple oral tablet for generic manufacturing challenges.
Mastered this topic? Test your knowledge with a full MCQ quiz.
Practice exam-style questions, track your score, and strengthen your recall.